Update on Advanced Liver Cancer Treatments

1
Update on Advanced Liver Cancer Treatments

• George Ansstas, MD

2
Worldwide HCC Statistics
3
Liver Cancer Incidence MalesRate Per 100,000
4
Liver Cancer Incidence FemalesRate Per 100,000
5
United States Health Crisis
6
Risk Factors for HCC
7
Cumulative Incidence of Hepatocellular Carcinoma
during Follow-up among 11,893 Men in Taiwan,
According to the Presence or Absence of Hepatitis
B Surface Antigen (HBsAg) and Hepatitis B e
Antigen (HBeAg) at Enrollment
Yang H et al. N Engl J Med 2002347168-174
8
Nodules Found on Screening or Surveillance
9
Prognostic Factors
10
Comparison of Staging Systems
11
Child-Pugh Score
12
Model for End-Stage Liver Disease (MELD)
13
Management of HCC
14
Barcelona Clinic Liver Cancer Proposed Treatment
Algorithm
15
(No Transcript)
16
Systemic Therapy
17
Single Agent Chemotherapy Response in HCC
18
Combination Chemotherapy Response in HCC
19
Phase III Doxorubicin vs PIAFUnresectable HCC
20
Molecular Pathogenesis of HCC
21
(No Transcript)
22
Angiogenesis Role in Tumor Growth
23
Why Target Angiogenesis in HCC?
24
Agents Targeting the VEGF Pathway
25
Sorafenib Targets Tumor Cell Proliferation and
Angiogenesis
26
(No Transcript)
27
Patient Characteristics
28
Overall Survival
29
(No Transcript)
30
Response Assessment
31
Treatment-Related Adverse Events
32
Clinical Impact
33
(No Transcript)
34
(No Transcript)
35
(No Transcript)
36
(No Transcript)
37
(No Transcript)
38
(No Transcript)
39
(No Transcript)
40
(No Transcript)
41
Phase II Sunitinib in Advanced HCC
42
Treatment-Related Adverse Events
43
Bevacizumab MOA in HCC
44
Phase II Bevacizumab in HCC
45
(No Transcript)
46
EGFR Receptors and Ligands
47
Anti-EGFR Targeted Approaches
48
Phase II Trials of EGFR Targeted Agents in HCC
49
Conclusions